• Press Releases

FDA Approves Investigational Device Exemption for SetPoint Bioelectronic Therapy Clinical Study in Rheumato...

Read Press Release from
December 11, 2017

SetPoint Medical Presents Early Data Showing Bioelectronic Medicine Accelerates Remyelination in Animal Mod...

Read Press Release from
October 30, 2017

SetPoint Secures $30 Million Series D Equity Financing

Read Press Release from
August 28, 2017

SetPoint Medical Appoints David Chernoff, MD as Chief Medical Officer

Read Press Release from
June 15, 2017

Global Venture Firm NEA Joins SetPoint Medical Syndicate of Investors

Read Press Release from
March 20, 2017

SetPoint Medical Presents Positive Results In Ongoing Crohn’s Disease Study

Read Press Release from
January 4, 2017

SetPoint Medical Presents Positive Clinical Results in Crohn’s Disease

Read Press Release from
October 19, 2016

SetPoint Medical’s Progress Fuels Corporate Headquarters Relocation

Read Press Release from
September 21, 2016

SetPoint Medical Expands Management Team to Support Advancement of Bioelectronic Medicine Platform

Read Press Release from
September 12, 2016

Breakthrough First-in-Human Study Shows Vagus Nerve Stimulation Significantly Reduces Rheumatoid Arthritis ...

Read Press Release from
July 4, 2016

SetPoint Announces $15 Million Equity Financing, Adds Major Strategic Investor

Read Press Release from
September 8, 2015

SetPoint Announces First Trial of Bioelectronic Therapy to Treat Crohn’s Disease

Read Press Release from
December 4, 2014